- Home
- NMM vs MESO Comparison
NMM vs MESO Comparison
Compare NMM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- MESO
- Stock Information
- Founded
- NMM 2007
- MESO 2004
- Country
- NMM Greece
- MESO Australia
- Employees
- NMM N/A
- MESO N/A
- Industry
- NMM Marine Transportation
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMM Consumer Discretionary
- MESO Health Care
- Exchange
- NMM Nasdaq
- MESO Nasdaq
- Market Cap
- NMM 1.3B
- MESO 1.3B
- IPO Year
- NMM 2007
- MESO N/A
- Fundamental
- Price
- NMM $44.51
- MESO $18.00
- Analyst Decision
- NMM
- MESO Buy
- Analyst Count
- NMM 0
- MESO 2
- Target Price
- NMM N/A
- MESO $24.00
- AVG Volume (30 Days)
- NMM 107.9K
- MESO 312.8K
- Earning Date
- NMM 11-04-2025
- MESO 08-28-2025
- Dividend Yield
- NMM 0.46%
- MESO N/A
- EPS Growth
- NMM N/A
- MESO N/A
- EPS
- NMM 10.24
- MESO N/A
- Revenue
- NMM $1,305,026,000.00
- MESO $17,198,000.00
- Revenue This Year
- NMM N/A
- MESO $288.50
- Revenue Next Year
- NMM $9.93
- MESO $167.17
- P/E Ratio
- NMM $4.40
- MESO N/A
- Revenue Growth
- NMM N/A
- MESO 191.39
- 52 Week Low
- NMM $28.37
- MESO $7.09
- 52 Week High
- NMM $61.18
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- NMM 42.81
- MESO 56.57
- Support Level
- NMM $43.02
- MESO $17.55
- Resistance Level
- NMM $45.50
- MESO $20.18
- Average True Range (ATR)
- NMM 1.29
- MESO 0.57
- MACD
- NMM -0.22
- MESO 0.02
- Stochastic Oscillator
- NMM 26.19
- MESO 50.17
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.